Mary Biles is an ex-TV producer, writer and educator with a background in holistic health. In the past, she’s written for the Huffington Post, CNN, and the BBC. While living in Southern Spain, her path crossed with the medicinal properties of the cannabis plant, and for the last three years she’s been writing about cannabinoids, in particular CBD, European medical cannabis research, and the endocannabinoid system. Now based in the UK, Mary is passionate about putting medical cannabis science into digestible terms; where possible going straight to source and interviewing the scientists behind the breakthroughs. Her website is here.
The European Union flipflops and declares that the CBD is not a narcotic, but the cannabis compound remains subject to international controls.
Many women with endometriosis use cannabis and CBD for pain relief, and cannabis therapeutics may also limit the spread of endometrial cells around the body.
CBDA, CBD’s raw botanical counterpart, shows promise as a therapeutic compound for treating cancer, anxiety, epilepsy, and treatment-resistant nausea and vomiting.
A Profile of Alan Shackelford, MD
There are many ways to mitigate stress by boosting endocannabinoid tone.
Managing anxiety is often the reason why people take cannabis or CBD products.
Could cannabidiol be a breakthrough therapy to replace or lessen the use of steroids?
End-of-life care is one of the less frequently discussed uses of medical cannabis. Palliative care, however, is perhaps the area of medicine that would most benefit from its clinical use.
November 1, 2018, was a day for celebration. With one stroke, the British government finally cast aside years of outdated dogma, moving ‘Cannabis Based Medicinal Products’ from Schedule 1 to Schedule 2. Unfortunately, a year has passed and only a handful of patients have actually been prescribed cannabis.
Polypharmacy - the use of five or more medications on a daily basis - is a modern-day health crisis. Could cannabis be the safer alternative prescribers and patients are looking for?